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Association of serum levels of lipoprotein A-I and lipoprotein A-I/A-II 
with high on-treatment platelet reactivity in patients with ST-segment 
elevation myocardial infarction
Introduction
Platelets are involved in both atherothrombosis and inflam-
mation, becoming a key factor in the pathophysiology of acute 
coronary syndrome (ACS), which includes ST-segment elevation 
myocardial infarction (STEMI) (1). Adequate platelet inhibition 
with dual antiplatelet therapy (DAPT) using aspirin and P2Y12 
antagonist (e.g., clopidogrel, prasugrel, ticagrelor, cangrelor) is 
an essential therapeutic target in STEMI patients and is strongly 
recommended by current guidelines (1, 2).
P2Y12 antagonists selectively inhibit the adenosine diphos-
phate (ADP) pathway of platelet activation by antagonizing one 
of the two platelet ADP receptors irreversibly (thienopyridines) 
or reversibly (ticagrelor) (3). The incidence of high on-treatment 
platelet reactivity (HPR) can be as high as one-third of individu-
als treated with clopidogrel, and HPR is present even in those 
receiving the more potent P2Y12 antagonists (4).
Inter-individual variability in the concentration of active 
metabolite and the level of platelet inhibition achieved follow-
ing the administration of the recommended doses of clopidogrel 
is multi-factorial and is contributed to by non-compliance, drug 
Objective: High-density lipoproteins (HDLs) are a very heterogeneous group of particles. Little is known about the impact of their subfractions 
including lipoprotein A-I (LpA-I) and lipoprotein A-I/A-II (LpA-I/A-II) on platelet function and high on-treatment platelet reactivity (HPR), particu-
larly in the acute phase of ST-segment elevation myocardial infarction (STEMI). The aim of the study was to evaluate the relationship between 
serum levels of LpA-I and LpA-I/A-II and HPR in STEMI patients.
Methods: Fifty-two consecutive STEMI patients (26.9% women, mean age 60.6±9.1 years) were enrolled into this study. Clinical and demographic 
data were collected and HDL subfractions were measured by rocket immunoelectrophoresis. Platelet reactivity was assessed using light trans-
mission aggregometry and quantitative flow cytometry.
Results: We found a positive correlation between platelet aggregation after both ADP-5 and ADP-20 stimulation and serum level of LpA-I. Com-
pared with subjects with satisfactory platelet response to clopidogrel, patients with HPR had 32.44% higher serum level of LpA-I (p=0.021). On 
the other hand, patients with HPR assessed by ADP-5 stimulation had 22.13% lower serum level of LpA-I/A-II (p=0.040). Regression analysis 
showed that LpA-I [odds ratio (OR) 1.03; 95% confidence interval (CI) 1-1.07; p=0.049] and current smoking (OR 0.18; 95% CI 0.04-0.81; p=0.025) 
were independent predictors of HPR. With receiver operating characteristic (ROC) curve analysis, we designated the cut-off point at serum level 
of 57.52 mg/dL for LpA-I for predicting HPR (AUC=0.71, p=0.010).
Conclusion: This study showed that higher serum level of LpA-I measured in the acute phase of STEMI is an independent risk factor for HPR. 
Our study is the first to demonstrate an important and distinct activity of LpA-I and LpA-I/A-II that can prove pleiotropic and different functions 
of HDL subfractions in acute STEMI. (Anatol J Cardiol 2018; 19: 374-81)
Keywords: high-density lipoproteins, lipoprotein A-I, platelets, high platelet reactivity, ST-elevation, myocardial infarction
ABSTRACT
#A.S. and R.G. contributed equally to this work.
Siniarski et al.
LpA-I is a predictor of high platelet reactivity in STEMI patients
Anatol J Cardiol 2018; 19: 374-81
DOI:10.14744/AnatolJCardiol.2018.63549 375
absorption, drug interactions, intrinsic high platelet reactivity, 
and genetic polymorphisms (5). Numerous clinical studies have 
demonstrated that suboptimal responses to clopidogrel and HPR 
are significantly related to increased cardiovascular mortality 
and thrombotic events in STEMI patients or in those undergoing 
percutaneous coronary intervention (PCI) (5). It was also dem-
onstrated that HPR was a major risk factor for post-PCI stent 
thrombosis (ST) and subsequent ACS (6). The relation between 
HPR and post-PCI ischemic events depended on the overall dis-
ease risk, post-PCI time interval (early vs. late), and ethnicity (6). 
HPR was proven to correlate with greater coronary atheroscle-
rosis and calcification (7).
There have been reports in which over 50% of patients with 
ACS had abnormal HDL-C levels, which were the most common 
forms of lipid abnormalities in this group of patients (8, 9). STEMI 
patients with low and very low levels of HDL-C have significantly 
increased in-hospital mortality compared with those with higher 
levels of HDL-C (9). Furthermore, the analysis of MIRACL trial 
showed that HDL-C level, but not LDL-C levels, is a better short-
term prognostic factor in predicting adverse cardiovascular 
events in patients after ACS (8). Several studies have confirmed 
the anti-inflammatory, anti-atherogenic, and anticoagulant prop-
erties of HDL-C are in part associated with the stimulation of pro-
duction of platelet activation inhibitors such as nitric oxide and 
prostacyclin (10-12). In addition, high level of HDL-C is related to 
low platelet activation in ACS patients treated with PCI (13, 14). 
On the other hand, there have also been reports on HDL-C’s 
procoagulant properties (15, 16). Human plasma HDL is a very het-
erogeneous group of lipoproteins with uncertain roles in cardio-
vascular risk (17-19). Apolipoprotein A-I (Apo A-I) and apolipopro-
tein A-II (Apo A-II) are found in two subfractions of HDL particles.
Apo A-I is a predominant protein of HDL particles. Gotto et 
al. (20) showed that Apo A-I level is a better predictor of the first 
cardiovascular event than any other lipid parameter. However, 
its oxidation by myeloperoxidase could change its properties 
and was associated with impairment on potential atheroprotec-
tive features of HDL particles (21). Apo A-II is the second major 
component of HDLs. It has been hypothesized that higher level of 
Apo A-II in HDL particles promotes procoagulant lipid redistribu-
tion and atherosclerosis progression, but these results remain 
unclear (22, 23). On the other hand, in the EPIC-Norfolk project, 
a negative association was found between the level of Apo A-II 
and development of CAD and its complications in potentially 
healthy population (24).
HDL particles containing only Apo A-I are called lipoprotein 
A-I (LpA-I) and consist of 25% of plasma Apo A-I; the rest of HDL 
particles contain both Apo A-I and Apo A-II and are called lipo-
protein A-I/A-II (LpA-I/A-II) (25).
To our knowledge, there is no information regarding the im-
pact of serum levels of LpA-I and LpA-I/A-II on platelet function, 
particularly in the acute phase of STEMI. Thus, the aim of this 
study was to evaluate the relationship between serum levels of 
LpA-I and LpA-I/A-II, and HPR in STEMI patients.
Methods
Study population
Fifty-two consecutive patients with acute STEMI within 12 h 
of the onset of symptoms were included in this study. Inclusion 
criteria were ≥45 years of age and first-ever clinical manifesta-
tion of CAD. STEMI diagnosis was established according to the 
Third Universal Definition of Myocardial Infarction by European 
Society of Cardiology. The study was performed according to the 
Helsinki Declaration with the approval of the local ethics commit-
tee. Each study participant provided written informed consent.
Exclusion criteria were as follows: previous treatment with 
hypolipidemic agents, acetylsalicylic acid (ASA), clopidogrel, 
proton pump inhibitor, or non-steroid anti-inflammatory drugs 12 
months prior to hospitalization; use of GP IIb/IIIa receptor inhibi-
tor during PCI; and concomitant severe systemic disease includ-
ing cancer.
When choosing a power of 90% and a two-sided alpha level 
of 0.05, at least 46 patients in the group were required to find the 
significance between LpA-I and ADP-5.
Lipid analysis
HDL-C subfractions and Apo A-I were determined by taking 
10 mL blood samples into tubes without any anticoagulant. After 
30–60 min at room temperature, blood samples were centrifuged 
for 10 min (3000 r/min). After clot separation, centrifugation was 
repeated. Serum was drained and portioned into parts and then 
stored in eppendorf tubes at −80°C until assayed. Basic labora-
tory results and all lipid parameters were measured during hos-
pital admission up to 12 h from symptom onset of chest pain.
LpA-I measurement
To measure LpA-I levels, we used rocket immunoelectropho-
resis. In serum agarose gel electrophoresis, excess concentra-
tion of anti-Apo A-I blocked the migration of particles contain-
ing Apo A-II (LpA-I/A-II). The height of generated characteristic 
rockets was proportional to the concentration of LpA-I particles. 
The concentration of the HDL-C-related Apo A-I in serum was 
measured by manual immunonephelometric assay. For further 
calculations, we used a previously defined formula:
Apo A-I (serum)=Apo A-I in (LpA-I) + Apo A-I in (LpA-I/A-II).
Other lipid analysis such as LDL-C, HDL-C, TG, and TC was 
performed using standard enzymatic assay.
Light transmission aggregometry
Blood-citrate vacutainer tubes were centrifuged for 10 min 
at 120 g and 10 min at 850 g to recover platelet-rich plasma 
(PRP) and platelet-poor plasma (PPP), respectively. Prior to the 
analysis, platelets were stimulated with 0.5 mmol/L solution of 
arachidonic acid (AA) and 5 and 20 µmol/L solution of adenos-
ine diphosphate (ADP-5 and ADP-20, respectively). Measure-
ments were performed 30-60 min after blood collection. Light 
transmission was adjusted using PRP to represent 0% and PPP 
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to represent 100% transmission for each measurement. Curves 
were recorded for 8 min or until the plateau phase was obtained. 
Platelet aggregation was expressed as the maximal percent-
age of change in light transmission from baseline using PPP as 
a reference. Aggregation was measured with the two-channel 
Chronology Aggregometer (Chrono-Log 490; Chrono-Log Corp., 
Havertown, Pennsylvania, USA).
Quantitative flow cytometry
Quantitative flow cytometry (FACSCalibur System, BD Biosci-
ence, Warsaw, Poland) was used with labeled monoclonal anti-
bodies against serine 239-phosphorylated vasodilator-stimulat-
ed phosphoprotein (VASP), followed by a secondary fluorescein 
isothiocyanate-conjugated polyclonal goat anti-mouse antibody. 
The mean fluorescence intensity (MFI) of the phosphorylated 
VASP levels after stimulation with prostaglandin E1 (PGE1) and 
PGE1+ADP was measured. In the analysis, we used P2Y12 recep-
tor activation-Platelet Reactivity Index (PRI) calculated accord-
ing to the following formula:
[(MFIPGE1)−(MFIPGE1+ADP)]/(MFIPGE1)×100%.
HPR was defined as PRI of ≥50% and aggregation of >46% 
after ADP-5 stimulation or >59% for ADP-20 was considered as 
inadequate response to clopidogrel (26). All platelet reactivity 
measurements were performed 12-24 h after the loading dose of 
clopidogrel and ASA (300-600 mg and 150-300 mg, respectively).
Statistical analysis
All continuous variables were expressed as mean±SD, and 
categorical variables were expressed as percentages. Continu-
ous data were tested for fit-to-normality by the D'Agostino-Pear-
son omnibus normality test. Normally distributed variables were 
presented as mean±SD and compared using independent sam-
ples t-test. Non-normally distributed variables were expressed 
in medians with interquartile range (IQR), and Mann-Whitney U 
test was used to determine the significant differences among 
the groups. Categorical variables were compared between the 
groups using the χ2 test or Fisher’s test when the expected popu-
lation size was small. The linear relationship between the two 
quantitative variables was investigated using the Pearson corre-
lation coefficient (normally distributed variables) or Spearman’s 
rank correlation coefficient (non-normally distributed variables). 
To determine platelet activation during clopidogrel treatment, 
univariate and multiple stepwise logistics regression analysis 
was performed. The final model was constructed by stepwise 
logistic regression to determine the independent determinants 
of HPR. To assess the optimum cut-off point, we used receiver 
operating characteristic (ROC) curve. Discriminatory ability of 
the model was tested using the area under the ROC curve (AUC). 
The level of significance was set at p<0.05. Statistical analysis 
was performed using the R statistical package for Windows (ver-
sion 2.15.1, The R Foundation for Statistical Computing, Vienna, 
Austria) and MedCalc for Windows (version 12.4, MedCalc Soft-
ware, Mariakerke, Belgium) was used.
Results
The study included 52 consecutive STEMI patients including 
14 women (26.9%) and 38 men (73.1%) aged 46-76 years (mean 
age of 60.6±9.14 years). The baseline demographic and clinical 
characteristics, laboratory results, evaluation of atherosclerotic 
lesions, culprit artery location, coronary angioplasty outcome, 
hospital course, and enzymatic assay with LV function param-
eter of the study population are presented in Table 1.
HDL-C subfractions and platelet reactivity
Lipids levels with HDL-C subfractions measurements, plate-
let reactivity, and numbers of patients diagnosed with HPR (ADP-
5, ADP-20, and PRI, respectively) are listed in Table 1. We have 
found a positive correlation between platelet aggregation after 
Figure 1. Concentration of HDL-C subfractions (LpA-I and LpA-I/A-II) in 
patients with and without HPR.
Data are presented as: median, interquartile range (IQR) and 1,5 IQR.
AA - aggregation after stimulation with arachidonic acid; ADP-5 (20) - aggregation after stimu-
lation with 5 (20) µmol of adenosine diphosphate; PRI - platelet reactivity index; HPR - high 
platelet reactivity during treatment
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both ADP-5 and ADP-20 stimulation and serum level of LpA-I 
(Table 2). Compared with subjects with satisfactory platelet re-
sponse to clopidogrel, patients with HPR assessed by ADP-20 
stimulation had 32.44% higher serum level of LpA-I (p=0.021). On 
the other hand, patients with HPR assessed by ADP-5 stimula-
tion had 22.13% lower serum level of LpA-I/A-II (p=0.040) (Table 
3 and Fig. 1).
HDL-C and Apo A-I did not differ between groups with vs. 
without HPR (Table 3). We have designated the cut-off point at 
57.52 mg/dL for LpA-I level in ROC curve for predicting HPR af-
ter stimulation with ADP-20 (Fig 2). Age, sex, weight, waist cir-
cumference, BMI, smoking history, current smoking, diabetes, 
impaired glucose tolerance, impaired fasting glucose, metabolic 
syndrome, mean platelet volume, and levels of HDL-C, LDL-C, 
triglycerides, total cholesterol, Apo A-I, LpA-I, LpA-I/A-II, glu-
cose and C-reactive protein (p<0.05 in a univariate analysis) 
were included in the final regression model. Multiple stepwise 
Table 1. General characteristics, lipids measurements, 
and platelets parameters of the study population (n=52)
Basic characteristics
Age (years) 60.6±9.1
Weight (kg) 77.5±13.5
Waist (cm) 94±12
BMI, kg/m2 26.6±3.9
Clinical data
Hypertension 27 (51.9)
Diabetes mellitus 11 (21.1)
IFG or IGT 11 (21.1)
Positive family history 13 (25)
Current cigarette smoking 21 (40.4)
Ex-smokers 13 (25)
Metabolic syndrome 26 (50)
Basic laboratory results
eGFR (MDRD) ml/kg/1.73 m2 80.6±16.9
AST, U/L 204.3±211.4
ALT, U/L 54.1±42.6
HGB, g/dL 14.4±1.3
RBC, 106/µL 4.7±0.5
PLT, 103/µL 224.2±66.0
CRP, mg/L 11.2±19.9
WBC, 103/µL 10.7±3.0
Glucose, mmol/L 7.8±2.4
Evaluation of atherosclerotic lesions
Gensini score, points 52±27.4
Culprit artery occlusion before procedure 35 (67.3)
IMT, mm 9.23±2.55
Hospital course 
Killip–Kimball classification I and II 49 (96.2)
Killip–Kimball classification III and IV 3 (3.8)
Recurrent ischemia 2 (3.8)
Necessity of urgent revascularization 1 (1.9)
AF/SVT 10 (19.2)
Complex ventricular arrhythmias 10 (19.2)
Atrioventricular block class II or III 7 (13.5)
Stroke or TIA 1 (1.9)
Cardiac arrest in the acute phase of MI 3 (3.8)
Deaths 0 (0)
Enzymatic assays and LV function parameter
TnI, ng/mL 74.6±72.2
CK, U/L 1914±1715
LVEF, % 49.1±7.5
Table 1. Cont.
Lipids measurements
HDL-C, mmol/L 1.3±0.3
LDL-C, mmol/L 3.5±0.9
TG, mmol/L 1.4±1.4
TC, mmol/L 5.6±1.2
Apo A I, mg/dL 140.9±30.4
LpA-I, mg/dL 59.3±23.8
LpA-I/A-II, mg/dL 80.0±30.9
LpA-I/HDL, % 42.3±15.3
[LpA-I/LpA-II]/HDL, % 57.7±15.3
Platelet reactivity
AA 2.8±1.7
ADP-5 52.2±23.3
ADP-20 53.1±23.1
PRI 45.7±26.4
MPV, fl 10.5±1.1
HPR (ADP-5) 33 (63.4)
HPR (ADP-20) 23 (44.2)
HPR (PRI) 27 (51.9) 
Data are given as mean±SD or number (percentage)
BMI - Body mass index; IFG - impaired fasting glucose; IGT - impaired glucose 
tolerance; eGFR - estimated glomerular filtration rate; AST -  aspartate transaminase; 
ALT - alanine transaminase; HGB - hemoglobin; RBC - red blood cells; PLT - platelets; 
CRP - C-reactive protein; WBC - white blood count; IMT - intima-media thickness; AF 
- atrial fibrillation; SVT - supraventricular tachycardia; TIA - transient ischemic attack; 
MI - myocardial infarction; TnI - cardiac troponin I; CK - creatine kinase; LVEF - left 
ventricle ejection fraction; SD - standard deviation; HDL-C - high-density lipoprotein 
cholesterol; LDL-C - low-density lipoprotein cholesterol; TG -  triglycerides; TC - total 
cholesterol; Apo A-I - apolipoprotein A I; LpA-I - HDL lipoprotein consisting only 
apolipoprotein A-I; LpA-I/A-II - HDL lipoprotein consisting both apolipoprotein A-I and 
A-II; AA - result of the optical aggregometry using arachidonic acid; ADP-5 (20) - result 
of the optical aggregometry using 5 (20) µmol/L of adenosine diphosphate; PRI - platelet 
reactivity index; MPV - mean platelet volume; HPR - high platelet reactivity during 
treatment; SD - standard deviation
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logistics regression analysis showed that LpA-I level and current 
cigarette smoking were independent predictors of HPR (Table 
4). With every 1 mg/dL of increasing LpA-I level, the risk of HPR 
grew by 3%. On the other hand, with cigarette smoking, the risk 
of HPR decreased more than five times. In the analyzed popula-
tion of STEMI patients, HDL-C subfractions did not prove to be 
useful in predicting in-hospital adverse cardiovascular events.
Discussion
To our knowledge, this is the first study to show that serum 
levels of LpA-I and LpA-I/A-II in STEMI patients are associated 
with platelet reactivity in response to DAPT with aspirin and 
clopidogrel. We have found that both current smoking and LpA-I 
altered the prevalence of HPR. Our study extends prior findings 
Table 2. Correlations between following lipids and platelet reactivity measurements
Parameter                                                Concentration in the acute phase of myocardial infarction
 HDL-C Apo A I LpA-I LpA-I/II
AA P=0.281 P=0.210 P=0.270 P=0.122
 r=0.12 r=0.16 r=0.16 r=-0.04
ADP-5 P=0.453 P=0.362 P=0.042 P=0.443
 r=-0.20 r=0.13 r=0.31 r=-0.10
ADP-20 P=0.112 P=0.781 P=0.041 P=0.790
 r=-0.17 r=0.07 r=0.32 r=-0.13
PRI P=0.762 P=0.334 P=0.762 P=0.392
 r=0.01 r=0.05 r=0.04 r=0.02
MPV P=0.810 P=0.240 P=0.550 P=0.671
 r=-0.008 r=0.04 r=0.13 r=0.03
Data are given as P-value and r-value
AA - result of the optical aggregometry using arachidonic acid; ADP-5 (20) - result of the optical aggregometry using 5 (20) µmol/L of adenosine diphosphate; PRI - platelet reactivity 
index; MPV - mean platelet volume; NS - not significant; HDL-C - high-density lipoprotein cholesterol; Apo A-I - apolipoprotein A-I; LpA-I - HDL lipoprotein consisting only apolipoprotein 
A I; LpA-I/A-II - HDL lipoprotein consisting both apolipoprotein A-I and A-II
Table 3. Concentration of high-density lipoprotein cholesterol subfractions and Apo A-I in acute phase of ST-segment 
elevation myocardial infarction in groups with and without high platelet reactivity
Variables     Concentration
                                 HDL                                  Apo A I                                LpA-I                             LpA-I/A-II
ADP-5 HPR (+) 1.13  136.1±28.6  63.0±23.2  71.8±26.5
  0.96-1.39 P=0.241  P=0.092  P=0.321  P=0.040
 HPR (-) 1.30
  0.98-1.43  148.9±33.5  53.5±25  92.2±37.1
ADP-20 HPR (+) 1.09  144.6±21  69±21.8  73.8±23.2
  0.91-1.39 P=0.330  P=0.190  P=0.021  P=0.542
 HPR (-) 1.28  137.7±36.78  52.1±23.5  83.5±37.3
  0.98 -1.43
PRI HPR (+) 1.21  135.9±28.9  59.7±27.8  76.2±22.7
  0.97-1.41 P=0.392  P=0.762  P=0.681  P=0.382
 HPR (-) 1.23  141±31.8  55.9±22.3  82.2±38.6
  0.96-1.41
Data are given as mean±SD or median (Q1-Q3).
NS - non-significant; AA - result of the optical aggregometry using arachidonic acid; ADP-5 (20) - result of the optical aggregometry using 5 (20) µmol/L of adenosine diphosphate; PRI - 
platelet reactivity index; HPR - high platelet reactivity during treatment; HDL-C - high-density lipoprotein cholesterol; Apo A-I - apolipoprotein A I; LpA-I - HDL lipoprotein consisting only 
apolipoprotein A I; LpA-I/A-II - HDL lipoprotein consisting both apolipoprotein A I and A II
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concerning the influence of HDL particles on platelet activation, 
particularly during clopidogrel treatment.
Previous studies have shown that HDL particles inhibited 
coagulation processes and platelet activation mostly by the in-
hibition of the tissue factor expression on the endothelial sur-
face (27). Furthermore, Apo A-II increased the activation of VIIc 
and Xc factors, which could indicate its prothrombotic proper-
ties (15). Nevertheless, Schäfer et al. (28) identified decreased 
HDL-C levels among factors determining HPR, both in patients 
with stable coronary artery disease and STEMI. Nofer et al. (29) 
showed that HDL particles led to the activation of protein kinase 
C, alkalization of platelets’ intracellular matrix, and inactivation 
of phospholipase C, thus preventing platelet activation.
There are no well-known explanations of the interactions 
between LpA-I and LpA-I/A-II levels and platelet activity. Dis-
covery of a scavenger receptor (SR-BI) gave us new insights into 
potential mechanisms involved in the inhibition of platelet activa-
tion. HDL particles binding to the SR-BI receptor resulted in the 
inhibition of thrombin-induced platelet aggregation, decrease in 
the binding of fibrinogen, decrease in the expression of P-se-
lectin, and mobilization of intracellular calcium ions (11). It has 
also been shown that platelets loaded with cholesterol esters 
are more sensitive to ADP (30). Experimental studies in recent 
years have shown that the P2Y12 receptor could present as an 
oligomer associated with membrane lipid rafts, which has been 
proven to split off from the rafts on clopidogrel treatment (31). 
Therefore, there is a possibility of significant influence of LpA-I 
and LpA-I/A-II levels on platelet reactivity and clinical respon-
siveness during clopidogrel treatment.
Assessment of platelet function during DAPT after PCI in 
STEMI patients is a useful diagnostic tool in predicting the inci-
dence of both ischemic and hemorrhagic complications (32). In 
our study, the prevalence of HPR on DAPT with aspirin and clopi-
dogrel varied from 44.2% to 63.4% (as assessed by ADP stimula-
tion). HPR occurrence in the study by Schäfer et al. (28) reached 
74%; hence, it was greater than that in our study (28). On the 
other hand, Cuisset et al. (33) showed a lower (44%) prevalence 
of HPR in patients with non-STEMI. These differences between 
studies may result from different populations studied and varied 
time-intervals between blood sample collection and clopidogrel 
administration.
The assessment of platelet reactivity in our study suggested 
that the “smokers’ paradox” can also be present in STEMI pa-
tients. Over fivefold reduction in the risk of HPR in the group of 
smokers can be explained by the induction of hepatic CYP1A2, 
also involved in the metabolism of clopidogrel and other expres-
sion of the P2Y12 receptor in smokers vs. non-smokers (34). It is 
still unclear whether obesity is associated with lower response 
to clopidogrel treatment. It was observed that obese individu-
als after PCI had lower short- and long-term mortality than do 
normal-weight patients. Our study did not confirm this “obesity 
paradox”. There is a study that has found that despite the initial 
period of low platelet response to loading dose of clopidogrel, af-
ter 30 days of clopidogrel administration, platelet response was 
similar between obese and normal-weight patients (35).
Study limitations
Several limitations of the study must be acknowledged. 
First, there was no correlation between HDL-C levels and clini-
cal outcomes, which probably resulted from the small popula-
tion of the study. Second, there is a lack of uniform criteria for 
HPR diagnosis, which is different for each technique and change 
dynamically in time. Hence, it seems that the diagnostic criteria 
may be different for each clinical situation. Some authors have 
proposed a different cut-off point value of PRI for predicting 
i.e., in-stent thrombosis (69.7%) and recurrence ischemia after 
NSTEMI (53%) and STEMI (57%) (28, 36). Third, blood samples 
were collected only once during the hospitalization period; thus, 
Table 4. Independent determinants of high platelet 
reactivity after stimulation with 20 µM ADP in the acute 
phase of ST-segment elevation myocardial infarction
Parameter OR 95% CI P-value
sex, y 1.07 0.98-1.16 0.221
smoking (currently) 0.18 0.04-0.81 0.025
glucose, mmol/L 1.35 0.90-2.03 0.450
LpA-I, mg/dL 1.03 1-1.07 0.049
Data are given as: OR, 95% CI
HPR - high platelet reactivity during treatment; STEMI - ST-elevation myocardial 
infarction; OR -odds ratio; CI - confidence interval; P - p-value; LpA-I - HDL lipoprotein 
consisting only apolipoprotein A-I, NS - non-significant
Figure 2. The ROC curve with designated cut-off point for LpA-I con-
centration in predicting HPR after stimulation with 20 µmol/L ADP.
LpA-I - HDL lipoprotein consisting only apolipoprotein A-I; LpA-I/A-II - HDL lipoprotein 
consisting both apolipoprotein A-I and A-II; HPR - high on-treatment platelet reactiv-
ity; ADP - adenosine diphosphate; AUC - area under the curve
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we could not track possible changes in platelet reactivity. Finally, 
a small group of patients made accurate comparisons between 
subgroups (i.e., smokers vs. non-smokers or between sexes) im-
possible; therefore, drawing conclusions from them could only 
be hypothetical.
Conclusion
This study demonstrated that higher serum levels of LpA-I 
measured during the acute phase of STEMI is an independent 
risk factor for HPR, which is a novel observation. There is a sig-
nificant negative correlation between serum level of LpA-I/A-II 
and HPR. Our study is the first to demonstrate an important and 
distinct activity of LpA-I and LpA-I/A-II, which can prove pleiotro-
pic and different functions of HDL subfractions in acute STEMI. 
The results of the present study are an interesting hypothesis 
and should be explored further in a larger study on a greater 
number of patients.
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